Cough in Idiopathic Pulmonary Fibrosis Clinical Trials Analysis, 2025: Targeted Anti-tussive Biologics, Neuromodulators, and Symptom-Focused Therapies Aim to Reduce Cough Burden and Improve Quality of Life | DelveInsight

DelveInsight's "Cough in Idiopathic Pulmonary Fibrosis Clinical Trials Analysis, 2025" captures an expanding set of symptomatic and mechanism-based approaches to address an under-treated, QoL-limiting symptom. Development includes neuromodulators that dampen hypersensitive cough reflexes, monoclonal antibodies against inflammatory mediators implicated in fibrotic cough, and novel inhaled agents to modify airway sensory signaling. Trials increasingly integrate digital cough monitoring, patient-reported cough-specific scales, and physiological cough reflex testing for objective and subjective assessment.

Registrational studies emphasize cough frequency/severity (objective cough counts), cough-related quality-of-life instruments, and functional endpoints such as sleep quality and activity. Safety, tolerability in patients with compromised pulmonary reserve, and interactions with antifibrotic therapies are key considerations. Regulatory pathways favor clear demonstration of meaningful symptomatic benefit and sustained reduction in cough burden with acceptable safety profiles for long-term use.

Interested in learning more about the current treatment landscape and the key drivers shaping the Cough in Idiopathic Pulmonary Fibrosis pipeline? Click here: https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report
• DelveInsight's cough in idiopathic pulmonary fibrosis pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline drugs for cough in idiopathic pulmonary fibrosis treatment.
• The leading cough in idiopathic pulmonary fibrosis companies include Trevi Therapeutics, Cellular Sciences/Emphycorp, NeRRe Therapeutics, Algernon Pharmaceuticals, Melius Pharma, and others are evaluating their lead assets to improve the cough in idiopathic pulmonary fibrosis treatment landscape.
• Key cough in idiopathic pulmonary fibrosis pipeline therapies in various stages of development include Haduvio (nalbuphine ER), Ifenprodi, ME-015, and others.
• In August 2025, Trevi Therapeutics reported Q2 financial results and provided updates on its investigational therapy HaduvioTM (oral nalbuphine ER), being developed for chronic cough in idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC).
• In February 2025, Boehringer Ingelheim revealed that its FIBRONEERTM-ILD trial also achieved its primary endpoint, showing improved FVC in patients with ILD, while maintaining a favorable safety and tolerability profile consistent with earlier IPF studies.
• In September 2024, Boehringer Ingelheim announced that its FIBRONEERTM-IPF trial-the largest IPF study to date-met its primary endpoint, demonstrating a significant improvement in Forced Vital Capacity (FVC) at week 52 versus placebo. The trial enrolled patients across 330+ sites in over 30 countries.
• In May 2024, Pliant Therapeutics reported positive topline results from a 12-week randomized, double-blind, placebo-controlled trial of bexotegrast (PLN-74809) at Massachusetts General Hospital, showing reductions in total lung collagen levels in patients with idiopathic pulmonary fibrosis (IPF).
• In December 2023, Trevi Therapeutics initiated its Phase IIb CORAL trial to evaluate HaduvioTM (oral nalbuphine ER) across three dose levels versus placebo in approximately 160 IPF patients with chronic cough.

Request a sample and discover the recent breakthroughs happening in the cough in idiopathic pulmonary fibrosis pipeline landscape @ https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cough in Idiopathic Pulmonary Fibrosis Overview
Chronic dry cough is a common and distressing symptom in idiopathic pulmonary fibrosis (IPF), affecting up to 80% of patients and significantly impacting quality of life. It is often persistent, worsening over time due to lung distortion, mucus production, and heightened cough reflex sensitivity. Comorbidities such as GERD, obstructive sleep apnea, and chronic sinusitis may contribute. Despite the lack of approved treatments specifically for IPF-related cough, management options include proton pump inhibitors, inhaled steroids, and low-dose opioids like morphine. Diagnosis of IPF involves assessing symptoms such as dry cough and exertional dyspnea, with high-resolution CT scans, pulmonary function tests, and exclusion of other interstitial lung diseases essential for accurate diagnosis and care planning.

Find out more about cough in idiopathic pulmonary fibrosis medication @ https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cough in Idiopathic Pulmonary Fibrosis Treatment Analysis: Drug Profile
Haduvio (nalbuphine ER): Trevi Therapeutics

Haduvio (nalbuphine ER) offers a unique mechanism for treating chronic cough by targeting key receptors involved in both central and peripheral cough pathways. It functions as a kappa opioid receptor agonist and a mu opioid receptor antagonist, enabling it to modulate the entire cough reflex arc-regardless of whether the cough originates in the lungs or the central nervous system. The therapy is currently being evaluated in a Phase II clinical trial for managing cough in patients with Idiopathic Pulmonary Fibrosis (IPF).

Orvepitant Maleate: NeRRe Therapeutics
Orvepitant Maleate is a selective NK-1 receptor antagonist developed by NeRRe Therapeutics, designed to reduce central neural hypersensitivity by blocking the action of substance P. This dual peripheral and central mechanism targets chronic cough effectively. Following promising results in patients with refractory or unexplained chronic cough, the drug is now in Phase II clinical trials to assess its efficacy in treating chronic cough associated with idiopathic pulmonary fibrosis (IPF).

Learn more about the novel and emerging cough in idiopathic pulmonary fibrosis pipeline therapies @ https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cough in Idiopathic Pulmonary Fibrosis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report
• Coverage: Global
• Key Cough in Idiopathic Pulmonary Fibrosis Companies: Trevi Therapeutics, Cellular Sciences/Emphycorp, NeRRe Therapeutics, Algernon Pharmaceuticals, Melius Pharma, and others.
• Key Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapies: Haduvio (nalbuphine ER), Ifenprodi, ME-015, others.

Dive deep into rich insights for drugs used for cough in idiopathic pulmonary fibrosis treatment; visit @ https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Cough in Idiopathic Pulmonary Fibrosis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutics
6. Cough in Idiopathic Pulmonary Fibrosis Pipeline: Late-Stage Products (Phase III)
7. Cough in Idiopathic Pulmonary Fibrosis Pipeline: Mid-Stage Products (Phase II)
8. Cough in Idiopathic Pulmonary Fibrosis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.